within Pharmacolibrary.Drugs.ATC.J;

model J01DD17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.11833333333333333,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.009300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.03183333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Cefcapene is an oral third-generation cephalosporin antibiotic primarily used for the treatment of bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. It is approved and widely used in Japan and some other countries but is not marketed in the United States or most of Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult Japanese volunteers following oral administration.</p><h4>References</h4><ol><li><p>Cazzola, M (2000). Novel oral cephalosporins. <i>Expert opinion on investigational drugs</i> 9(2) 237–246. DOI:<a href=&quot;https://doi.org/10.1517/13543784.9.2.237&quot;>10.1517/13543784.9.2.237</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11060674/&quot;>https://pubmed.ncbi.nlm.nih.gov/11060674</a></p></li><li><p>Okamoto, K, et al., &amp; Aihara, M (2020). Poor penetration of cefcapene into aqueous humor after oral administration of cefcapene pivoxil to patients undergoing cataract surgery. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 26(2) 312–315. DOI:<a href=&quot;https://doi.org/10.1016/j.jiac.2019.08.004&quot;>10.1016/j.jiac.2019.08.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31481306/&quot;>https://pubmed.ncbi.nlm.nih.gov/31481306</a></p></li><li><p>Fujimoto, M (2001). Pharmacokinetics of cefcapene pivoxil and AS-924 in gastrectomized patients. <i>International journal of antimicrobial agents</i> 18(5) 489–494. DOI:<a href=&quot;https://doi.org/10.1016/s0924-8579(01)00446-0&quot;>10.1016/s0924-8579(01)00446-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11711266/&quot;>https://pubmed.ncbi.nlm.nih.gov/11711266</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DD17;
